Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis

被引:81
作者
Alonzi, T
Newton, IP
Bryce, PJ
Di Carlo, E
Lattanzio, G
Tripodi, M
Musiani, P
Poli, V
机构
[1] Natl Inst Infect Dis L Spallanzani, IRCCS, I-00149 Rome, Italy
[2] Univ Dundee, Wellcome Trust Bioctr, Dept Biochem, Dundee DD1 5EH, Scotland
[3] Univ Chieti, Dept Oncol & Neurosci, Chieti, Italy
[4] Univ Roma La Sapienza, Dipartimento Biotecnol Cellulari & Ematol, Fondaz Ist Pasteur Cenci Bolognetti, Rome, Italy
[5] Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy
基金
英国惠康基金;
关键词
conditional gene inactivation; inflammation; inflammatory bowel disease; STAT3; enterocolitis;
D O I
10.1016/j.cyto.2003.12.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have generated mice in which the gene encoding the transcription factor STAT3 can be inactivated in multiple cell types by triggering the endogenous production of type I interferon. Gene inactivation is particularly effective in the liver and the adipose tissue. as well as in macrophages and gut epithelial cells. Upon induction Of the Mutation, mice develop a wasting syndrome culminating in an aggressive and fatal form of enterocolitis, limited to the large intestine, within 2-3 weeks after the treatment. The disease is characterised by massive infiltration Of the gut mucsosa by macrophages, granulocytes and CD4+ cells, increased expression of endothelial adhesion molecules and high production of the cytokines interleukin (IL)-6, IL-12, interferon-gamma and IL-10. IL-12 p40 plays a pivotal role in disease development as in vivo treatment with neutralising antibodies completely prevents its, onset. Interestingly, oral treatment with wide spectrum antibiotics does not have any effect on either the onset or the development of colitis. Taken together. these data show that STAT3 plays a crucial role in the maintenance of intestinal homeostasis and possibly in mediating specialised cell functions in the intestinal epithelium. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:45 / 56
页数:12
相关论文
共 42 条
[1]   Roles of STAT3 defined by tissue-specific gene targeting [J].
Akira, S .
ONCOGENE, 2000, 19 (21) :2607-2611
[2]   Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene activation in the liver [J].
Alonzi, T ;
Maritano, D ;
Gorgoni, B ;
Rizzuto, G ;
Libert, C ;
Poli, V .
MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (05) :1621-1632
[3]   Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation:: Evidence in Crohn disease and experimental colitis in vivo [J].
Atreya, R ;
Mudter, J ;
Finotto, S ;
Müllberg, J ;
Jostock, T ;
Wirtz, S ;
Schütz, M ;
Bartsch, B ;
Holtmann, M ;
Becker, C ;
Strand, D ;
Czaja, J ;
Schlaak, JF ;
Lehr, HA ;
Autschbach, F ;
Schürmann, G ;
Nishimoto, N ;
Yoshizaki, K ;
Ito, H ;
Kishimoto, T ;
Galle, PR ;
Rose-John, S ;
Neurath, MF .
NATURE MEDICINE, 2000, 6 (05) :583-588
[4]  
BARKIN R, 1992, SEMIN VET MED SURG, V7, P117
[5]   Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses [J].
Berg, DJ ;
Davidson, N ;
Kuhn, R ;
Muller, W ;
Menon, S ;
Holland, G ;
ThompsonSnipes, L ;
Leach, MW ;
Rennick, D .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (04) :1010-1020
[6]   Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects [J].
Betz, UAK ;
Bloch, W ;
van den Broek, M ;
Yoshida, K ;
Taga, T ;
Kishimoto, T ;
Addicks, K ;
Rajewsky, K ;
Müller, W .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 188 (10) :1955-1965
[7]   Acquired increase in leucocyte binding by intestinal microvascular endothelium in inflammatory bowel disease [J].
Binion, DG ;
West, GA ;
Volk, EE ;
Drazba, JA ;
Ziats, NP ;
Petras, RE ;
Fiocchi, C .
LANCET, 1998, 352 (9142) :1742-1746
[8]   The role of STATs in transcriptional control and their impact on cellular function [J].
Bromberg, J ;
Darnell, JE .
ONCOGENE, 2000, 19 (21) :2468-2473
[9]  
Cavallo F, 1999, CANCER RES, V59, P414
[10]  
Davidson NJ, 1998, J IMMUNOL, V161, P3143